1. any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior vte, acute confirmed symptomatic vte, acute coronary syndrome. 2. anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis: 1. any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke, 2. previous vte, 3. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable. 3. any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding. 4. intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial hemorrhage. 5. hemoglobin \<8 g/dl and platelet count \<50 x 109 cells/l confirmed by recent laboratory test (\<90 days). 6. subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy. 7. severe renal insufficiency (baseline creatinine clearance \<30 ml/min calculated using the cockcroft-gault formula) confirmed by recent laboratory test (\<90 days). 8. contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. 9. current use of dual antiplatelet therapy. 10. participation in other interventional studies over the past 30 days. 11. non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.

1. any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior vte, acute confirmed symptomatic vte, acute coronary syndrome. 2. anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis: 1. any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke, 2. previous vte, 3. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable. 3. any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding. 4. intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial hemorrhage. 5. hemoglobin \<8 g/dl and platelet count \<50 x 109 cells/l confirmed by recent laboratory test (\<90 days). 6. subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy. 7. severe renal insufficiency (baseline creatinine clearance \<30 ml/min calculated using the cockcroft-gault formula) confirmed by recent laboratory test (\<90 days). 8. contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. 9. current use of dual antiplatelet therapy. 10. participation in other interventional studies over the past 30 days. 11. non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.

any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior vte, acute confirmed symptomatic vte, acute coronary syndrome. anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis: any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke, previous vte, histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable. any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding. intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial hemorrhage. hemoglobin <8 g/dl and platelet count <50 x 109 cells/l confirmed by recent laboratory test (<90 days). subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy. severe renal insufficiency (baseline creatinine clearance <30 ml/min calculated using the cockcroft-gault formula) confirmed by recent laboratory test (<90 days). contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. current use of dual antiplatelet therapy. participation in other interventional studies over the past 30 days. non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.

any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior vte, acute confirmed symptomatic vte, acute coronary syndrome. anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis: any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke, previous vte, histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable. any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding. intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial hemorrhage. hemoglobin <8 g/dl and platelet count <50 x 109 cells/l confirmed by recent laboratory test (<90 days). subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy. severe renal insufficiency (baseline creatinine clearance <30 ml/min calculated using the cockcroft-gault formula) confirmed by recent laboratory test (<90 days). contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. current use of dual antiplatelet therapy. participation in other interventional studies over the past 30 days. non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.

1. any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior vte, acute confirmed symptomatic vte, acute coronary syndrome. 2. anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis: 1. any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke, 2. previous vte, 3. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable. 3. any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding. 4. intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial hemorrhage. 5. hemoglobin <8 g/dl and platelet count <50 x 109 cells/l confirmed by recent laboratory test (<90 days). 6. subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy. 7. severe renal insufficiency (baseline creatinine clearance <30 ml/min calculated using the cockcroft-gault formula) confirmed by recent laboratory test (<90 days). 8. contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. 9. current use of dual antiplatelet therapy. 10. participation in other interventional studies over the past 30 days. 11. non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.

1. any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior vte, acute confirmed symptomatic vte, acute coronary syndrome. 2. anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis: 1. any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke, 2. previous vte, 3. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable. 3. any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding. 4. intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial hemorrhage. 5. hemoglobin <8 g/dl and platelet count <50 x 109 cells/l confirmed by recent laboratory test (<90 days). 6. subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy. 7. severe renal insufficiency (baseline creatinine clearance <30 ml/min calculated using the cockcroft-gault formula) confirmed by recent laboratory test (<90 days). 8. contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. 9. current use of dual antiplatelet therapy. 10. participation in other interventional studies over the past 30 days. 11. non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.